Triplet (FOLFOXIRI) Versus Doublet (FOLFOX or FOLFIRI) Regimen as First Line Treatment in Metastatic Colorectal Carcinoma, a Prospective Phase II, Randomized Controlled Trial

BACKGROUND: The outcomes of treatment of metastatic colorectal cancer (mCRC) is still unsatisfactory. Several trials approved that, the upfront treatment with triplet regimen included fluorouracil, leucovorin, irinotecan and oxaliplatin improved the outcomes of patients with metastatic disease as co...

Descripción completa

Detalles Bibliográficos
Autores principales: Khali, Khaled Ahmed, Musalm, Hanan Selim, Hassan, Mohamed Abdulla, Mahmoud, Inas Abdou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9924351/
https://www.ncbi.nlm.nih.gov/pubmed/36308367
http://dx.doi.org/10.31557/APJCP.2022.23.10.3421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9924351/
https://www.ncbi.nlm.nih.gov/pubmed/36308367
http://dx.doi.org/10.31557/APJCP.2022.23.10.3421

Ejemplares similares